Moderna and Merck’s personalized mRNA vaccine raised two-year recurrence-free survival to 82.2%, from 70% with Keytruda alone; despite the Phase 3 success, Moderna shares plunged 18%, overall survival remains unproven and US approval is pending | Read More in ynet – Culture
US has asked Musk to change Starlink services in Ukraine, Middle East for years, fears misuseLess than a day after stabbing attack, Chabad man returns to wrapping tefillin in ManhattanLarge share of Israelis prefer holding new elections if no coalition formed, IDI survey shows
UK teachers could be barred from wearing pro-Palestine badges amid antisemitism concerns – report
Three men allege late Lindsey Graham paid for sex; one says he was 17 and filmed without consent
Three years after October 7, 75% of Israel’s border-area Jews say war will shape their vote
Report: Iran advancing sophisticated plots to assassinate senior US officials
US quietly moves diplomats and families across Middle East as fears of wider war grow
Ben Gvir slams Netanyahu’s campaign to draw votes away from Otzma Yehudit
IDF, Shin Bet launch counterterrorism operation in Hebron after deadly shooting attack
Netanyahu warns of possible banking sanctions, proposes digital currencies as alternative
US Ambassador to Turkey: Could there be an Iran strike this weekend? AbsolutelyUS has asked Musk to change Starlink services in Ukraine, Middle East for years, fears misuseLess than a day after stabbing attack, Chabad man returns to wrapping tefillin in ManhattanAmid Ukraine uproar, sources say US had asked Musk to block Starlink for Hezbollah, HouthisLarge share of Israelis prefer holding new elections if no coalition formed, IDI survey shows